<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PEGVISOMANT</span><br/>(peg-vis'o-mant)<br/><span class="topboxtradename">Somavert<br/></span><b>Classifications:</b> <span class="classification">hormones &amp; synthetic substitutes</span>; <span class="classification">growth hormone modifier</span>; <span class="classification">growth hormone receptor antagonist</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>15 mg, 20 mg, 10 g powder for injection</p>
<h1><a name="action">Actions</a></h1>
<p>A growth hormone (GH) receptor antagonist that binds to GH receptors on cell surfaces where it blocks the binding of GH and
         interferes with its action and ability to stimulate production of insulin-like growth factor I (IGF-1).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Produces a significant decrease in the level of serum insulin-like growth factor I (IGF-1), the primary mediator of GH effects
         on body tissues.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of acromegaly when other treatments have failed or are inappropriate.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to pegvisomant; hypersensitivity to latex; lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pituitary tumors; diabetes mellitus; hepatic and/or renal impairment; pregnancy (category B); children, and elderly.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Acromegaly</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 40 mg loading dose, then 10 mg once daily. Adjust dose in 5 mg increments, up to 30 mg/d, based on serum IGF-I concentrations.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Allow vials to reach room temperature, then reconstitute by adding 1 mL of supplied diluent (sterile water for injection)
            to the vial. Direct diluent against the glass wall of vial, then mix by gently rolling between palms of hands to dissolve.
            DO NOT SHAKE. Solution should be clear and colorless. Use within 6 h of reconstitution.
         </li>
<li>Inject SC and exercise caution not to inject IV.</li>
<li>Rotate injection sites and do not use any site more than once every 12 mo.</li>
<li>Store vials of powder at 2°8° C (36°46° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Asthenia, flu-like syndrome, infection, injection site reactions, back pain, paresthesias, peripheral edema. <span class="typehead">CNS:</span> Dizziness. <span class="typehead">CV:</span> Angina, chest pain, hypertension, MI. <span class="typehead">GI:</span> Elevated liver function tests, diarrhea, nausea, vomiting. <span class="typehead">Metabolic:</span> Hypercholesterolemia, hypoglycemia, and low titer nonneutralizing antigrowth hormone antibodies. <span class="typehead">Musculoskeletal:</span> Arthralgia. <span class="typehead">Respiratory:</span> Sinusitis. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Similar to growth hormone and may cross-react with <b>
<i>growth hormone assays.</i>
</b> Do not use these assays to monitor pegvisomant therapy.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">opiate agonists</span> may lead to higher <b>pegvisomant</b> dosing requirements; may need to decrease doses of <b>insulin,</b>
<span class="classification">oral antidiabetic agents</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 57% absorbed from SC injection site. <span class="typehead">Peak:</span> 3377 h. <span class="typehead">Half-Life:</span> 6 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Montior CV status with baseline and periodic BP measurements.</li>
<li>Monitor diabetics for loss of glycemic control.</li>
<li>Withhold drug and notify physician for significant elevation in AST/ALT or S&amp;S of hepatitis.</li>
<li>Lab tests: IGF-1 levels 46 wk after initiation of therapy or any dose adjustment, then q6mo after IGF-1 levels have
            normalized; periodic LFTs and lipid profile; frequent blood glucose monitoring, especially if diabetic.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report promptly any of the following: chest pain or tightness, signs of infection (e.g., fever, chills, flu-like symptoms).</li>
<li>Discontinue drug and notify physician immediately if jaundice appears.</li>
<li>Do not drive or engage in other hazardous activities until reaction to drug is known.</li>
<li>Do not breast feed without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>